Engineering and design software provider PTC (NASDAQ:PTC) will be reporting earnings tomorrow afternoon. Here’s what to ...

PTC PTC underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.

Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shot up 6.1% during trading on Monday after Cantor Fitzgerald raised their price target on the stock from $76.00 to $113.00. Cantor ...

Inc., a leading provider of software solutions for product design, manufacturing, and service, continues to navigate a challenging macroeconomic environment while positioning itself for future growth.

Get a deeper insight into the potential performance of PTC Inc. (PTC) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for ...

PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price ...

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

Barclays analyst Saket Kalia maintained a Buy rating on PTC (PTC – Research Report) today and set a price target of $215.00. The company’s ...

The long-awaited Bunyoro University (BU) in Hoima district remains stalled due to political interference, blackmail and ...